OptimizeRx Corporation

NasdaqCM:OPRX Stock Report

Market Cap: US$193.1m

OptimizeRx Past Earnings Performance

Past criteria checks 0/6

OptimizeRx's earnings have been declining at an average annual rate of -52.3%, while the Healthcare Services industry saw earnings growing at 5.7% annually. Revenues have been growing at an average rate of 23.6% per year.

Key information

-52.3%

Earnings growth rate

-48.2%

EPS growth rate

Healthcare Services Industry Growth1.7%
Revenue growth rate23.6%
Return on equity-13.9%
Net Margin-24.6%
Next Earnings Update14 May 2024

Recent past performance updates

Recent updates

OptimizeRx Corporation's (NASDAQ:OPRX) 36% Jump Shows Its Popularity With Investors

Jan 09
OptimizeRx Corporation's (NASDAQ:OPRX) 36% Jump Shows Its Popularity With Investors

Analyst Forecasts Just Became More Bearish On OptimizeRx Corporation (NASDAQ:OPRX)

Aug 24
Analyst Forecasts Just Became More Bearish On OptimizeRx Corporation (NASDAQ:OPRX)

OptimizeRx Corporation (NASDAQ:OPRX) Shares May Have Slumped 38% But Getting In Cheap Is Still Unlikely

Aug 16
OptimizeRx Corporation (NASDAQ:OPRX) Shares May Have Slumped 38% But Getting In Cheap Is Still Unlikely

Is Now An Opportune Moment To Examine OptimizeRx Corporation (NASDAQ:OPRX)?

May 31
Is Now An Opportune Moment To Examine OptimizeRx Corporation (NASDAQ:OPRX)?

OptimizeRx: A Top Candidate For My Speculative 'Bio Boom' Portfolio

Oct 12

Is Now The Time To Look At Buying OptimizeRx Corporation (NASDAQ:OPRX)?

Sep 23
Is Now The Time To Look At Buying OptimizeRx Corporation (NASDAQ:OPRX)?

OptimizeRx extends reach with Cooler Screens Partnership

Jul 26

OptimizeRx: A Small-Cap Digital Health Technology Gem With Near-Term Inflection In Profitability

Jun 27

The Strong Earnings Posted By OptimizeRx (NASDAQ:OPRX) Are A Good Indication Of The Strength Of The Business

Nov 16
The Strong Earnings Posted By OptimizeRx (NASDAQ:OPRX) Are A Good Indication Of The Strength Of The Business

Why We Think OptimizeRx Corporation's (NASDAQ:OPRX) CEO Compensation Is Not Excessive At All

Aug 13
Why We Think OptimizeRx Corporation's (NASDAQ:OPRX) CEO Compensation Is Not Excessive At All

A Look At The Fair Value Of OptimizeRx Corporation (NASDAQ:OPRX)

Jul 15
A Look At The Fair Value Of OptimizeRx Corporation (NASDAQ:OPRX)

Here's Why We're Not At All Concerned With OptimizeRx's (NASDAQ:OPRX) Cash Burn Situation

Jun 24
Here's Why We're Not At All Concerned With OptimizeRx's (NASDAQ:OPRX) Cash Burn Situation

Investors Will Want OptimizeRx's (NASDAQ:OPRX) Growth In ROCE To Persist

May 10
Investors Will Want OptimizeRx's (NASDAQ:OPRX) Growth In ROCE To Persist

Estimating The Fair Value Of OptimizeRx Corporation (NASDAQ:OPRX)

Mar 29
Estimating The Fair Value Of OptimizeRx Corporation (NASDAQ:OPRX)

Don't Ignore The Fact That This Insider Just Sold Some Shares In OptimizeRx Corporation (NASDAQ:OPRX)

Feb 21
Don't Ignore The Fact That This Insider Just Sold Some Shares In OptimizeRx Corporation (NASDAQ:OPRX)

What Percentage Of OptimizeRx Corporation (NASDAQ:OPRX) Shares Do Insiders Own?

Jan 27
What Percentage Of OptimizeRx Corporation (NASDAQ:OPRX) Shares Do Insiders Own?

Revenue & Expenses Breakdown
Beta

How OptimizeRx makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqCM:OPRX Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 2372-18540
30 Sep 2363-14510
30 Jun 2362-14520
31 Mar 2362-14520
31 Dec 2262-11490
30 Sep 2263-10460
30 Jun 2264-7430
31 Mar 2264-3390
31 Dec 21610330
30 Sep 21571300
30 Jun 21521260
31 Mar 2147-1230
31 Dec 2043-2230
30 Sep 2034-6220
30 Jun 2029-7210
31 Mar 2027-5200
31 Dec 1925-3170
30 Sep 1924-1150
30 Jun 19241130
31 Mar 19220120
31 Dec 18210110
30 Sep 18190100
30 Jun 1816-190
31 Mar 1814-180
31 Dec 1712-270
30 Sep 1710-270
30 Jun 179-260
31 Mar 178-260
31 Dec 168-260
30 Sep 167-220
30 Jun 168-110
31 Mar 167-110
31 Dec 157-110
30 Sep 157010
30 Jun 157010
31 Mar 157010
31 Dec 147-110
30 Sep 146-110
30 Jun 146-110
31 Mar 145-110
31 Dec 135010
30 Sep 134040
30 Jun 133030

Quality Earnings: OPRX is currently unprofitable.

Growing Profit Margin: OPRX is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: OPRX is unprofitable, and losses have increased over the past 5 years at a rate of 52.3% per year.

Accelerating Growth: Unable to compare OPRX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: OPRX is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (15.4%).


Return on Equity

High ROE: OPRX has a negative Return on Equity (-13.88%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.